Not currently recruiting at University of California Health
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at UC Irvine
- Dates
- study startedcompletion around
- Principal Investigator
- by Robert Fearn (uci)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Robert Fearn (uci)
Assistant Health Sciences Professor, Medicine, School of Medicine
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Takeda
- Links
- More about this study
- ID
- NCT06233461
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 268 study participants
- Last Updated